ADVM - アバランシェ・バイオテクノロジ―ズ (Adverum Biotechnologies Inc.) アバランシェ・バイオテクノロジ―ズ

 ADVMのチャート


 ADVMの企業情報

symbol ADVM
会社名 Adverum Biotechnologies Inc (アバランシェ・バイオテクノロジ―ズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Adverum Biotechnologies Inc. is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. It has collaboration agreements with Regeneron Pharmaceuticals to research develop and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Its core capabilities include clinical development and in-house manufacturing specifically in process development and assay development.   アバランシェ・バイオテクノロジ―ズは、米国のバイオ医薬品会社。眼科疾患用の新規遺伝子治療薬の発見、開発および商業化に従事。主な製品は、滲出型加齢黄斑変性症の遺伝子治療薬「AVA-101」やX染色体連鎖性網膜分離症(XLRS)の遺伝子治療薬「AVA-311」。本社は、カリフォルニア州メンロ・パ―ク。   Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema.
本社所在地 1035 O'Brien Drive Menlo Park CA 94025 USA
代表者氏名 Paul B. Cleveland ポールB.クリーブランド
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 650-272-6269
設立年月日 38899
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 78人
url www.avalanchebiotech.com
nasdaq_url https://www.nasdaq.com/symbol/advm
adr_tso
EBITDA EBITDA(百万ドル) -65.87600
終値(lastsale) 5.51
時価総額(marketcap) 345444347.74
時価総額 時価総額(百万ドル) 359.86400
売上高 売上高(百万ドル) 1.63300
企業価値(EV) 企業価値(EV)(百万ドル) 124.98800
当期純利益 当期純利益(百万ドル) -54.46500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Adverum Biotechnologies Inc revenues decreased 23% to $709K. Net loss increased 31% to $36M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development -gross increase of 39% to $20.8M (expense) Stock-based Compensation in SGA increase from $1.5M to $6.1M (expense).

 ADVMのテクニカル分析


 ADVMのニュース

   Eye-popping stocks: Alibaba Group Holding Limited (NYSE:BABA -0.99%), Adverum Biotechnologies, Inc. (NASDAQ:ADVM -7.51%)  2021/09/06 22:20:02 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Eye-popping stocks: Alibaba Group Holding Limited (NYSE:BABA -0.99%), Adverum Biotechnologies, Inc. (NASDAQ:ADVM -7.51%) appeared first on Stocks Equity .
   Adverum Appoints Global Regulatory Leader Jim Wang, Ph.D., as Senior Vice President, Head of Regulatory Affairs  2021/08/23 13:00:00 Intrado Digital Media
REDWOOD CITY, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Jim Wang, Ph.D., has been appointed senior vice president, head of regulatory affairs. Reporting directly to Laurent Fischer, M.D., Adverums president and chief executive officer, Dr. Wang will lead regulatory strategies and execution for the companys product pipeline. He brings more than 17 years of global regulatory experience, including a decade in gene therapy that includes the submission and approval for LUXTURNA ® , the first gene therapy targeting a genetic disease that received regulatory approval in both the U.S. and EU.
   Global Alpha- Antitrypsin Deficiency Treatment Market 2026 Business Growth | Adverum Biotechnologies, IncAlnylam Pharmaceuticals, Inc.  2021/08/16 03:15:57 Jumbo News
LP INFORMATION recently released a research report on the Alpha- Antitrypsin Deficiency Treatment analysis, which studies the Alpha- Antitrypsin Deficiency Treatment industry coverage, current market competitive status, and market outlook and forecast by 2026. Global Alpha- Antitrypsin Deficiency Treatment Market 2021-2026 Research Report categorizes the global Alpha- Antitrypsin Deficiency Treatment by key players, product type, applications and regions,etc. The []
   Adverum Biotechnologies EPS misses by $0.07  2021/08/05 21:25:01 Seeking Alpha
   Bright Stock in Review: Adverum Biotechnologies, Inc. (NASDAQ:ADVM), ION Geophysical Corporation (NYSE:IO)  2021/08/03 22:53:20 Stock Equity
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) with the stream of -1.89% also noticed, India ION Geophysical Corporation (NYSE:IO) encountered a rapid change of -2.86% in the last hour of Tuesdays trading session. The post Bright Stock in Review: Adverum Biotechnologies, Inc. (NASDAQ:ADVM), ION Geophysical Corporation (NYSE:IO) appeared first on Stocks Equity .
   The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data  2021/05/04 12:10:20 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV ) BioNTech SE – ADR (NASDAQ: BNTX ) (moving on momentum imparted by vaccine news flow) GT Biopharma Inc (NASDAQ: GTBP ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Lantheus Holdings Inc (NASDAQ: LNTH ) Orthopediatrics Corp (NASDAQ: KIDS ) Quest Diagnostics Incorporated (NYSE: DGX ) West Pharmaceutical Services, Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 3) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aptinyx Inc. (NASDAQ: APTX ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) AVROBIO, Inc. (NASDAQ: AVRO ) (reacted to the need for conducting a registrational trial for its gene therapy candidate for Fabry disease) Aziyo Biologics, Inc. (NASDAQ: AZYO ) Celyad Oncology SA (NASDAQ: CYAD ) Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ) Cyclerion Therapeutics, Inc. (NASDAQ: CYCN ) Decibel Therapeutics, Inc.
   Adverum's Wet AMD Gene Therapy Shows Long Term Benefit In Treatment-Experienced Patients  2021/05/03 10:07:49 Benzinga
Adverum Biotechnologies Inc (NASDAQ: ADVM ) has announced new long-term data from the OPTIC Phase 1 trial of ADVM-022 single intravitreal (IVT) injection gene therapy in patients with neovascular or wet age-related macular degeneration (wet AMD). Safety and efficacy data from patients followed for a median of 88 and 68 weeks at 2 x 10^11 vg/eye dose (for Cohorts 2 & 3, respectively) and 104 and 36 weeks at the 6 x 10^11 vg/eye dose (for Cohorts 1 & 4, respectively). The data was presented at the Association for Research in Vision and … Full story available on Benzinga.com
   Why Adverum Biotechnologies Stock Is Plummeting Today  2021/04/29 19:54:32 Benzinga
Adverum Biotechnologies (NASDAQ: ADVM ) shares are trading lower after the … Full story available on Benzinga.com
   The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx  2021/04/29 12:15:49 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ: AXNX ) Boston Scientific Corporation (NYSE: BSX ) (reacted to first-quarter results) Celcuity Inc. (NASDAQ: CELC ) Celldex Therapeutics, Inc. (NASDAQ: CLDX) Galectin Therapeutics Inc. (NASDAQ: GALT ) Horizon Therapeutics Public Limited Company (NASDAQ: HZNP ) Insulet Corporation (NASDAQ: PODD ) Integra LifeSciences Holdings Corporation (NASDAQ: IART ) (announced first-quarter results) Lantheus Holdings, Inc. (NASDAQ: LNTH ) MacroGenics, Inc. (NASDAQ: MGNX ) NuVasive, Inc. (NASDAQ: NUVA) PRA Health Sciences, Inc. (NASDAQ: PRAH ) ShockWave Medical, Inc. (NASDAQ: SWAV ) Verastem, Inc. (NASDAQ: VSTM ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 28) Akoya Biosciences, Inc. (NASDAQ: AKYA ) Decibel Therapeutics, Inc. (NASDAQ: DBTX ) IRadimed Corporation (NASDAQ: IRMD ) Lucira Health, Inc. (NASDAQ: LHDX ) Mesoblast Limited (NASDAQ: MESO ) Protara Therapeutics, Inc. (NASDAQ: TARA ) PTC Therapeutics, Inc. (NASDAQ: PTCT ) Stocks In Focus Adverum Shares Sink On Serious Adverse Event Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) announced a suspected unexpected serious adverse reaction of hypotony, which is clinically relevant decrease in ocular pressure, in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema.
   Adverum's Stock Crashes After DME Gene Therapy Trial Derails On One Patient's Serious Adverse Event  2021/04/29 09:32:17 Benzinga
Adverum Biotechnologies Inc (NASDAQ: ADVM ) stock has cratered in reaction to a Suspected Unexpected Serious Adverse Reaction of hypotony (clinically-relevant decrease in ocular pressure). The event was reported in the INFINITY Phase 2 trial evaluating ADVM-022 gene therapy … Full story available on Benzinga.com
   The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq  2021/03/18 12:16:32 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 17) AngioDynamics, Inc. (NASDAQ: ANGO ) Anixa Biosciences, Inc. (NASDAQ: ANIX ) BioAtla, Inc. (NASDAQ: BCAB ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) IDEAYA Biosciences, Inc. (NASDAQ: IDYA ) Immatics N.V. (NASDAQ: IMTX ) ( announced positive Phase 1 readout for a trio of candidates in solid tumors) NGM Biopharmaceuticals, Inc. (NASDAQ: NGM ) NuVasive, Inc. (NASDAQ: NUVA ) Omnicell, Inc. (NASDAQ: OMCL ) Oncternal Therapeutics, Inc. (NASDAQ: ONCT ) Organogenesis Holdings Inc. (NASDAQ: ORGO ) PLx Pharma Inc. (NASDAQ: PLXP ) Sierra Oncology, Inc. (NASDAQ: SRRA ) Silverback Therapeutics, Inc. (NASDAQ: SBTX ) STRATA Skin Sciences, Inc. (NASDAQ: SSKN ) Urovant Sciences Ltd. (NASDAQ: UROV ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 17) Foghorn Therapeutics Inc. (NASDAQ: FHTX ) Galapagos NV (NASDAQ: GLPG ) Galecto, Inc. (NASDAQ: GLTO ) Stocks In Focus Translate Bio mRNA Product Candidate For Cystic Fibrosis Fails To Improve Lung Function In Phase 1/2 Study Translate Bio (NASDAQ: TBIO ) announced a second interim analysis from the Phase 1/2 study of MRT5005 in patients with cystic fibrosis, showing that repeat dosing was generally safe and well tolerated, with no serious adverse events.
   Hereditary Angioedema Market to Demonstrates a Spectacular Growth with CSL Behring, Shire Plc., Pharming Healthcare, Inc., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Adverum Biotechnologies  2021/03/18 06:37:38 OpenPR
Hereditary angioedema (HAE) is characterized by acute skin and mucosal edema caused by an autosomal dominant mutation of the genes. The current treatments of the condition include the HAE drugs which can be administered intravenously, subcutaneously or taken orally. The
   Chardan Capital Stick to Their Buy Rating for Adverum Biotechnologies By Investing.com  2021/03/03 05:45:10 Investing.com
Chardan Capital Stick to Their Buy Rating for Adverum Biotechnologies
   RBC Capital Stick to Their Buy Rating for Adverum Biotechnologies By Investing.com  2021/03/03 01:46:24 Investing.com
RBC Capital Stick to Their Buy Rating for Adverum Biotechnologies
   Adverum Biotechnologies Should you short it before the Earnings result? : Stock market Insights & financial analysis  2021/03/01 16:55:00 Stock Market Daily
Adverum Biotechnologies announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アバランシェ・バイオテクノロジ―ズ ADVM Adverum Biotechnologies Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)